Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Free Cash Flow (2016 - 2025)

Wave Life Sciences' Free Cash Flow history spans 11 years, with the latest figure at -$33.8 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 22.77% year-over-year to -$33.8 million; the TTM value through Dec 2025 reached -$188.2 million, down 23.85%, while the annual FY2025 figure was -$188.2 million, 23.85% down from the prior year.
  • Free Cash Flow reached -$33.8 million in Q4 2025 per WVE's latest filing, up from -$44.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $85.0 million in Q1 2023 to a low of -$63.2 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$29.0 million, with a median of -$33.8 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: plummeted 377.36% in 2022, then soared 312.15% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$7.0 million in 2021, then tumbled by 377.36% to -$33.6 million in 2022, then grew by 0.15% to -$33.6 million in 2023, then crashed by 30.18% to -$43.7 million in 2024, then increased by 22.77% to -$33.8 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's Free Cash Flow are -$33.8 million (Q4 2025), -$44.9 million (Q3 2025), and -$46.3 million (Q2 2025).